Serum interleukin 6 (IL-6) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis;Stȩżnie interleukiny 6 (IL-6) w surowicy koreluje ze stȩżeniem metaloproteinaz i ich tkankowych inhibitorów w reumatoidalnym zapaleniu stawów

Polskie Archiwum Medycyny Wewnetrznej

Volumn 109, Issue 2, 2003, Pages 119-123

  Klimiuk, Piotr Adrian ^b   Sierakowski, Stanisław ^a   Chwiećko, Justyna ^b  

^a Klin Reumatol/Chorob W AM   (Poland)

^b NONE

Author keywords

IL 6; Interleukin 6; Metalloproteinases; MMPs; Rheumatoid arthritis; TIMPs; Tissue inhibitors of metalloproteinases

Indexed keywords

C REACTIVE PROTEIN; GELATINASE B; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; METHOTREXATE; SALAZOSULFAPYRIDINE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PREDICTION; RHEUMATOID ARTHRITIS; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; MIDDLE AGED; PREDICTION AND FORECASTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SULFASALAZINE; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0141608843     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bresnihan B.: Pathogenesis of joint damage in rheumatoid arthritis. J. Rheumatol., 1999, 26, 717.
2. van den Berg W.B., van Lent PL.: The role of macrophages in chronic arthritis. Immunobiology, 1996, 195, 614.
3. Klimiuk P.A., Sierakowski S.: Cytokiny w reumatoidalnym zapaleniu stawów. I. Cytokiny prozapalne. Pol. Merk. Lek., 2001, 11, 510.
4. Suffredini A.F., Fantuzzi C., Badolato R. i wsp.: New insights into the biology of the acute phase response. J. Clin. Immunol., 1999, 19, 203.
5. Dinant H.J., Dijkmans B.A.C.: New therapeutic targets for rheumatoid arthritis. Pharm. World Sci., 1999, 21, 49.
6. Jikko A., Wakisaka T., Iwamoto M. i wsp.: Effects of interleukin-6 on proliferation and proteoglycan metabolism in articular chondrocyte cultures. Cel Biol. Int., 1998, 22, 615.
7. Klimiuk P.A., Sierakowski S.: Cytokiny i ich antagoniści w leczeniu reumatoidalnego zapalenia stawów. Przegl. Lek., 2002, 59, 108.
8. Nagase H., Okada Y.: Proteinases and matrix degradation. [w:] Textbook of rheumatology. (red.) Kelley W.N., Harris E.D., Ruddy S., Sledge C.B., W.B. Saunders Company, Philadelphia, 1997, 323.
9. Firestein G.S.: Etiology and pathogenesis of rheumatoid arthritis. [w:] Textbook of rheumatology. (red.) Kelley W.N., Harris E.D., Ruddy S., Sledge C.B., W.B. Saunders Company, Philadelphia, 1997, 851-897.
10. Arnett F.C., Edworthy S.M., Bloch D.A. i wsp.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum., 1988, 31, 315.
11. Abbas A.K., Lichtman A.H., Pober J.S.: Cytokines. [w:] Cellular and molecularimmunology. (red.) Abbas A.K., Lichtman A.H., Pober J.S., W.B. Saunders Company, Philadelphia 1994, 240.
12. Klimiuk P.A., Yang H., Goronzy J.J., Weyand C.M.: Production of cytokines and metalloproteinases in rheumatoid arthritis is T cell dependent. Clin. Immunol., 1999, 90, 65.
13. Klimiuk P.A., Sierakowski S., Latosiewicz R., Cylwik B., Skowroński J., Chwiećko J.: Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology (Oxford), 2002, 41, 78.
14. Franke S., Herrmann D., Hein G. i wsp.: Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy. Eur. J. Med. Res., 1997, 29, 401.
15. Houssiau F.A., Devogelaer J., Van Damme J., Nagant De Deuxchaisnes C., Van Snick J.: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum., 1988, 31, 784.6
16. van Leeuwen M.A., Westra J., Limburg P.C. i wsp.: Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann. Rheum. Dis., 1995, 54, 33.
17. Ichikawa Y., Yamada C., Horiki T., Hoshina Y., Uchiyama M.: Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol., 1998, 16, 533.
18. Keyszer G., Lambiri L, Nagel R. i wsp.: Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J. Rheumatol., 1999, 26, 251.
19. So A., Chamot A.M., Peclat V., Gerster J. C.: Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatology, 1999, 38, 407.